Natco Pharma Ltd. (NATCOPHARM) 52 Week Low Streak: Why the decline persists

Natco Pharma Ltd. (NATCOPHARM) has now set a fresh 52-week low for its second straight session, and the Natco Pharma Ltd. 52 Week Low Streak is down 1.27% across the run. The latest trough stood at Rs 786.2, while the latest traded price was Rs 790 at 14 October 2026 at 9:22 AM IST. Univest data confirms the pattern, but it does not establish a company-specific cause for the repeated decline.

With a market capitalisation of Rs 15,697.36 crore, the Natco Pharma Ltd. 52 Week Low Streak matters because it shows a repeated one-year breakdown rather than a single-day slip. For readers tracking Natco Pharma Ltd. 52 Week Low Streak, the focus is not only the latest tick lower, but also how the fresh low compares with the earlier trough and how the valuation now looks after two sessions of weakness.

What the Repeated 52-Week Lows Show

Natco Pharma Ltd. 52 Week Low Streak now confirms a repeated one-year low pattern over two consecutive sessions, with the full streak down 1.27%. The first low in the run was set on 13 October 2026, and the latest session pushed the stock to Rs 786.2 again. Natco Pharma Ltd. 52 Week Low Streak is therefore best understood as an extended decline pattern, not as a one-off close to the low.

For Natco Pharma Ltd. 52 Week Low Streak, the practical takeaway is simple: the stock has not yet reclaimed the level that would break the sequence of yearly lows. Because no company-specific catalyst is confirmed, the streak itself becomes the main fact to track. Natco Pharma Ltd. 52 Week Low Streak also matters because repeated lows often draw attention to whether the market is still willing to reprice the business lower session after session.

Natco Pharma Ltd. (NATCOPHARM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 15,697.36 crore
P/E Ratio	13.54x
P/B Ratio	1.66x
ROE	16.3%
ROCE	17.16%
EPS	Rs 58.33
Book Value Per Share	Rs 476.47
Dividend Yield	0.63%

Natco Pharma Ltd. (NATCOPHARM) fundamental metrics show P/E 13.54x, P/B 1.66x, ROE 16.3%, ROCE 17.16%. Taken on their own, these numbers offer context rather than a trading signal.

Natco Pharma Ltd. has a market capitalisation of Rs 15,697.36 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.54x, P/B at 1.66x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.3% and ROCE of 17.16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 58.33, book value per share of Rs 476.47, dividend yield of 0.63%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.8x, median ROE of 11.53%, median ROCE of 13.32%. They set out the fundamental picture and are not a rating on the stock.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	13.54x
Benchmark Median P/E	31.8x
Benchmark Average P/E	46.93x
Benchmark P/E Range	3.11x to 663.29x
Company P/B Ratio	1.66x
Benchmark Median P/B	2.91x
Company ROE	16.3%
Benchmark Median ROE	11.53%
Company ROCE	17.16%
Benchmark Median ROCE	13.32%
Company Market Capitalisation	Rs 15,697.36 crore
Benchmark Median Market Cap	Rs 819.72 crore

Natco Pharma Ltd. (NATCOPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.

Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.54x, which is below the benchmark median of 31.8x, a difference of -57.42%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Natco Pharma Ltd. (NATCOPHARM) has a ROE of 16.3%, which is above the benchmark median of 11.53%, a difference of +41.37%. Natco Pharma Ltd. (NATCOPHARM) has a ROCE of 17.16%, which is above the benchmark median of 13.32%, a difference of +28.83%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Alembic Pharmaceuticals Ltd.	APLLTD	15,482.29	22.59	2.68	12.35	11.74
Eris Lifesciences Ltd.	ERIS	16,072.17	24.78	3.96	19.23	14.47
Jubilant Pharmova Ltd.	JUBLPHARMA	15,115.78	42.66	2.11	5.97	8.69
Glenmark Life Sciences Ltd.	ALIVUS	16,518.28	27.39	4.74	18.41	24.61
Astrazeneca Pharma India Ltd.	ASTRAZEN	14,717.5	86.77	16.28	23.02	31.24

Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.54x compared with the displayed peer median of 27.39x. The comparison is relative and should not be read as a recommendation. Its ROE of 16.3% compares with a peer median of 18.41% across the companies shown in the table. ROCE stood at 17.16% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of Rs 15,697.36 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching Natco Pharma Ltd.

This section is about the repeated decline, not a trading call. Natco Pharma Ltd. 52 Week Low Streak has now stretched to a second straight session, the streak move is down 1.27% across the run, and the latest low at Rs 786.2 matches the day’s trough. Those facts keep the stock on the watchlist for anyone following yearly lows.

• Natco Pharma Ltd. 52 Week Low Streak has now stretched to a second straight session.
• The cumulative move across the run is down 1.27%.
• The latest low at Rs 786.2 matches the day’s trough.
• Valuation remains below the industry median on both P/E and P/B.
• ROE and ROCE remain above the benchmark medians.

About Natco Pharma Ltd.

Natco Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within Healthcare. For readers tracking Natco Pharma Ltd. 52 Week Low Streak, that context matters because it helps frame the business against sector benchmarks rather than as a standalone price chart. The company’s market capitalisation of Rs 15,697.36 crore, P/E of 13.54 and P/B of 1.66 give the streak its valuation setting.

The company’s EPS of Rs 58.33 and book value of Rs 476.47 show the base that remains in place even as the share price keeps making fresh yearly lows. Natco Pharma Ltd. 52 Week Low Streak does not change those business inputs; it only changes how the market is pricing them at this point. That is why Natco Pharma Ltd. share price today should be read together with company financials, sector analysis and peer comparison.

Track Natco Pharma Ltd. Share Price on Univest

Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Metric	Value
Current Price	Rs 790
Previous Close	Rs 789.6
Today's Move	+Rs 0.4 (+0.05%)
Open	Rs 788.6
High	Rs 794.85
Low	Rs 786.2
Market Capitalisation	Rs 15,697.36 crore

Natco Pharma Ltd. (NATCOPHARM) traded at Rs 790 versus the previous close of Rs 789.6, a rise of 0.05%. The stock opened at Rs 788.6, reached a high of Rs 794.85, touched a low of Rs 786.2.

Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener and Univest market blogs to review live stock data, yearly-low lists and related market analysis.

Natco Pharma Ltd. 52 Week Low Streak can be followed alongside the latest share price, market capitalisation, valuation ratios and peer context on Univest. If the stock keeps printing new yearly lows, the next step is to watch whether the streak extends or whether price stabilises above the most recent trough.

Frequently Asked Questions

What does Natco Pharma Ltd. 52 Week Low Streak mean?

Ans. Natco Pharma Ltd. 52 Week Low Streak means the stock has set a fresh 52-week low in consecutive sessions. In this case, the pattern now spans two straight trading days and shows a repeated yearly low.

How many sessions has Natco Pharma Ltd. 52 Week Low Streak lasted?

Ans. Natco Pharma Ltd. 52 Week Low Streak has lasted for two consecutive sessions. The first low in the run was on 13 October 2026, and the latest session again marked a fresh 52-week trough.

By how much has Natco Pharma Ltd. 52 Week Low Streak moved?

Ans. The Natco Pharma Ltd. 52 Week Low Streak is down 1.27% across the streak. That figure captures the cumulative move over the consecutive lows and is more useful than only the latest intraday change.

What is the latest low in Natco Pharma Ltd. 52 Week Low Streak?

Ans. The latest low in Natco Pharma Ltd. 52 Week Low Streak is Rs 786.2. The same level was also the day’s low, so the stock again matched its fresh 52-week trough during the session.

Is there a confirmed company-specific reason for Natco Pharma Ltd. 52 Week Low Streak?

Ans. No company-specific cause is confirmed in the data for Natco Pharma Ltd. 52 Week Low Streak. The repeated low is confirmed, but the reason behind the continued decline is not established here.

How does Natco Pharma Ltd. 52 Week Low Streak look on valuation?

Ans. Natco Pharma Ltd. 52 Week Low Streak leaves the stock on 13.54 times earnings and 1.66 times book value. Both are below the latest Univest industry medians, which means the streak is happening at a lower valuation than many peers.

How do the return ratios compare in Natco Pharma Ltd. 52 Week Low Streak?

Ans. Natco Pharma Ltd. 52 Week Low Streak comes with ROE of 16.3% and ROCE of 17.16%. Both are above the benchmark medians in the same industry set. ROE stands at 16.3%.

How does Natco Pharma Ltd. 52 Week Low Streak compare with peers?

Ans. Natco Pharma Ltd. 52 Week Low Streak shows a lower P/E and P/B than several listed pharma peers in the benchmark set. That makes the stock look lower-valued on valuation, even as the repeated low keeps pressure on the price.

What should investors watch next in Natco Pharma Ltd. 52 Week Low Streak?

Ans. Investors should watch whether Natco Pharma Ltd. 52 Week Low Streak extends further or whether the stock starts trading above the latest trough. The key markers are the next session’s low and how the price behaves relative to the current.